EA200970262A1 - Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам - Google Patents

Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам

Info

Publication number
EA200970262A1
EA200970262A1 EA200970262A EA200970262A EA200970262A1 EA 200970262 A1 EA200970262 A1 EA 200970262A1 EA 200970262 A EA200970262 A EA 200970262A EA 200970262 A EA200970262 A EA 200970262A EA 200970262 A1 EA200970262 A1 EA 200970262A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
compositions
methods
methods relating
glucagon receptors
Prior art date
Application number
EA200970262A
Other languages
English (en)
Inventor
Хай Ян
Шоу-Фен Сильвия Ху
Томас С. Бун
Ричард А. Линдберг
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA200970262A1 publication Critical patent/EA200970262A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

В настоящем изобретении предложены композиции и способы, относящиеся к антигенсвязывающим белкам, в частности антителам, специфично связывающимся с глюкагоновым рецептором человека. В изобретении также предложены нуклеиновые кислоты, кодирующие указанные антигенсвязывающие белки, а также антитела и способы получения и применения указанных антител, включая способы лечения и предотвращения диабета 2 типа и связанных с ним нарушений, путем введения указанных антител субъекту, нуждающемуся в таком лечении или предотвращении.
EA200970262A 2006-09-20 2007-09-19 Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам EA200970262A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84620206P 2006-09-20 2006-09-20
US96897707P 2007-08-30 2007-08-30
PCT/US2007/020349 WO2008036341A2 (en) 2006-09-20 2007-09-19 Compositions and methods relating to glucagon receptor antibodies

Publications (1)

Publication Number Publication Date
EA200970262A1 true EA200970262A1 (ru) 2009-10-30

Family

ID=39201088

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970262A EA200970262A1 (ru) 2006-09-20 2007-09-19 Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам

Country Status (19)

Country Link
US (2) US7947809B2 (ru)
EP (1) EP2074149B1 (ru)
JP (1) JP5513888B2 (ru)
KR (1) KR20090059161A (ru)
CN (1) CN101589062B (ru)
AR (1) AR062895A1 (ru)
AU (1) AU2007297652B2 (ru)
BR (1) BRPI0715017A8 (ru)
CA (1) CA2662613C (ru)
CL (1) CL2007002668A1 (ru)
CR (1) CR10736A (ru)
EA (1) EA200970262A1 (ru)
ES (1) ES2444012T3 (ru)
IL (1) IL197241A0 (ru)
MX (2) MX353319B (ru)
NO (1) NO20091534L (ru)
PE (1) PE20080846A1 (ru)
TW (1) TW200820985A (ru)
WO (1) WO2008036341A2 (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009000586A1 (es) * 2008-03-27 2010-06-04 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
CN102482350B (zh) * 2009-09-08 2015-08-05 株式会社新药 作用于胰高血糖素受体的抗体及其应用
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6050671B2 (ja) * 2012-12-07 2016-12-21 ダイキン工業株式会社 空気調和装置の配管ユニットの製造方法および空気調和装置の施工方法
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
SG11201508264UA (en) 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
MX2016002870A (es) 2013-09-05 2017-02-23 Amgen Inc Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles.
AU2015243246B2 (en) * 2014-04-10 2018-09-06 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
MX2016014761A (es) 2014-05-16 2017-05-25 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
US10626179B2 (en) 2014-06-08 2020-04-21 Remd Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
KR20230153495A (ko) * 2014-10-01 2023-11-06 메디뮨 리미티드 티카그렐로에 대한 항체 및 이의 사용 방법
CN111018987B (zh) * 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
WO2016102657A1 (en) 2014-12-23 2016-06-30 Novo Nordisk A/S Alpha-cell re-generation combined with conversion to beta cells
CA2973964A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
CN107614695B (zh) 2015-04-02 2022-01-25 瑞美德生物医药科技有限公司 用胰高血糖素受体拮抗性抗体治疗肥胖症和非酒精性脂肪肝病或非酒精性脂肪性肝炎的方法
CA2999747A1 (en) 2015-09-04 2017-03-09 Remd Biotherapeutics, Inc. Methods for treating heart failure using glucagon receptor antagonistic antibodies
WO2017062693A1 (en) * 2015-10-07 2017-04-13 Remd Biotherapeutics, Inc. Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies
KR101896882B1 (ko) 2015-11-30 2018-09-11 앱클론(주) Vegfr2에 특이적으로 결합하는 항체
US20190002577A1 (en) * 2016-01-04 2019-01-03 Remd Biotherapeutics, Inc. Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies
EP3493847A4 (en) * 2016-08-03 2020-04-08 REMD Biotherapeutics, Inc. COMBINATION OF GLUCAGON RECEPTOR ANTAGONISTS AND PI3K PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER
CN109922831A (zh) 2016-08-30 2019-06-21 瑞泽恩制药公司 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
EP3573651A4 (en) * 2017-01-27 2020-10-14 NGM Biopharmaceuticals, Inc. GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE
JP2020510646A (ja) * 2017-02-20 2020-04-09 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
JP2020513813A (ja) 2017-03-14 2020-05-21 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
CN107011414B (zh) * 2017-05-31 2020-04-24 浙江省农业科学院 具有降血糖功能的三肽spf及其用途
US20210130480A1 (en) 2017-08-22 2021-05-06 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
JP2022516439A (ja) 2018-12-21 2022-02-28 ジエンス ヘンルイ メデイシンカンパニー リミテッド 二特異性タンパク質
US20220235140A1 (en) * 2019-05-29 2022-07-28 Hedgehog, Inc. Antibody with enhanced binding affinity for endothelin receptor type a
AU2020329217A1 (en) * 2019-08-12 2022-07-28 Aptevo Research And Development Llc 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
EP4034556A1 (en) 2019-09-26 2022-08-03 Amgen Inc. Methods of producing antibody compositions
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
AU2021411581A1 (en) * 2020-12-31 2023-07-06 Novarock Biotherapeutics, Ltd. Antibodies to tnfr2 and uses thereof
WO2022182664A1 (en) * 2021-02-23 2022-09-01 10X Genomics, Inc. A method for epitope binning of novel monoclonal antibodies
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776725A (en) * 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
US5639863A (en) * 1994-06-21 1997-06-17 Dan; Michael D. Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
US5889167A (en) * 1996-05-22 1999-03-30 Merck & Co., Inc. Synthetic glucagon binding proteins
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
WO2002045494A2 (en) 2000-12-06 2002-06-13 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
MXPA05005921A (es) * 2002-12-02 2005-10-19 Abgenix Inc Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
WO2006005469A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
NZ556029A (en) * 2004-12-21 2010-04-30 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta

Also Published As

Publication number Publication date
JP2010504331A (ja) 2010-02-12
JP5513888B2 (ja) 2014-06-04
EP2074149B1 (en) 2013-11-06
KR20090059161A (ko) 2009-06-10
EP2074149A2 (en) 2009-07-01
US20110223160A1 (en) 2011-09-15
CA2662613A1 (en) 2008-03-27
CN101589062B (zh) 2014-08-20
AU2007297652B2 (en) 2012-02-16
MX2009003093A (es) 2009-06-05
CR10736A (es) 2009-06-30
IL197241A0 (en) 2011-08-01
US7947809B2 (en) 2011-05-24
WO2008036341A2 (en) 2008-03-27
WO2008036341A3 (en) 2009-02-05
BRPI0715017A2 (pt) 2013-05-28
CL2007002668A1 (es) 2008-05-09
BRPI0715017A8 (pt) 2018-04-03
PE20080846A1 (es) 2008-08-23
NO20091534L (no) 2009-04-28
TW200820985A (en) 2008-05-16
MX353319B (es) 2018-01-05
US20090041784A1 (en) 2009-02-12
CN101589062A (zh) 2009-11-25
ES2444012T3 (es) 2014-02-21
CA2662613C (en) 2014-01-28
US8158759B2 (en) 2012-04-17
AR062895A1 (es) 2008-12-10
AU2007297652A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA108066C2 (uk) Білки, що зв'язуються з cgrp-рецепторами людини
EA201691176A1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ ЧЕЛОВЕКА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С β-КЛОТО, РЕЦЕПТОРАМИ FGF И ИХ КОМПЛЕКСАМИ
EA200701292A1 (ru) Композиции, содержащие антитела против рецептора igf-1, и способы получения антител
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
EA200900514A1 (ru) Антигенсвязывающие белки il-17 рецептора а
EA201100694A1 (ru) Антитело к cd38 человека и его применение
RU2430111C3 (ru) Молекулы антител с улучшенными свойствами
EA201190018A1 (ru) Миостатинсвязывающие белки
ATE509953T1 (de) Antikörper gegen den erythropoietinrezeptor und verwendungen davon
TW200745164A (en) Gene recombination antibodies composition
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
UA116614C2 (uk) Антитіло до фактора d і його застосування
EA201492149A8 (ru) St2-антигенсвязывающие белки
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201070596A1 (ru) Гуманизированные антитела против tl1a
GEP20115324B (en) Tweak binding antibodies
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
BRPI0711908B8 (pt) anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
DE60328195D1 (de) Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf